Tarsus Pharmaceuticals (TARS) News Today $62.26 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$62.28 +0.02 (+0.04%) As of 05/22/2026 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Lisanti Capital Growth LLC Buys 21,330 Shares of Tarsus Pharmaceuticals, Inc. $TARSMay 24 at 5:59 AM | marketbeat.comUBS Group AG Has $5.48 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARSMay 21, 2026 | marketbeat.comTarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS InvestorsMay 20, 2026 | tipranks.comTarsus Pharmaceuticals Inc Ordinary Shares TARSMay 19, 2026 | morningstar.comMTarsus Pharmaceuticals, Inc. $TARS Stake Raised by TimesSquare Capital Management LLCMay 19, 2026 | marketbeat.comTarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance RaiseMay 15, 2026 | seekingalpha.comCena was diagnosed with Demodex blepharitis, which he admittedly "didn't even know existed"May 14, 2026 | yahoo.comTarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million AmericansMay 14, 2026 | globenewswire.comAssessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term GainsMay 13, 2026 | finance.yahoo.comTarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS) and Tarsus Pharmaceuticals (TARS)May 11, 2026 | theglobeandmail.comIs It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings?May 11, 2026 | finance.yahoo.comWhat is HC Wainwright's Estimate for TARS Q2 Earnings?May 11, 2026 | marketbeat.comLifesci Capital Has Negative Estimate for TARS Q2 EarningsMay 11, 2026 | marketbeat.comVanguard Group Inc. Purchases 127,470 Shares of Tarsus Pharmaceuticals, Inc. $TARSMay 10, 2026 | marketbeat.comF m Investments LLC Makes New $3.21 Million Investment in Tarsus Pharmaceuticals, Inc. $TARSMay 10, 2026 | marketbeat.comWhat is HC Wainwright's Estimate for TARS FY2027 Earnings?May 8, 2026 | marketbeat.comLifeSci Capital Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)May 8, 2026 | theglobeandmail.comWhat is Lifesci Capital's Forecast for TARS Q1 Earnings?May 8, 2026 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Moderate Buy" from AnalystsMay 8, 2026 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesMay 7, 2026 | globenewswire.comTarsus Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMay 7, 2026 | finance.yahoo.comLifesci Capital Has Pessimistic Outlook of TARS Q4 EarningsMay 7, 2026 | marketbeat.comTarsus Pharmaceuticals Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comTarsus Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comTarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comTarsus Reports First Quarter 2026 Financial Results and Recent Business AchievementsMay 6, 2026 | finance.yahoo.comTarsus Pharmaceuticals (NASDAQ:TARS) Issues Earnings Results, Beats Expectations By $0.27 EPSMay 6, 2026 | marketbeat.comTarsus Reports First Quarter 2026 Financial Results and Recent Business AchievementsMay 6, 2026 | globenewswire.comHC Wainwright Issues Pessimistic Outlook for TARS EarningsMay 6, 2026 | marketbeat.comTarsus Pharmaceuticals, Inc. Q1 2026 earnings previewMay 5, 2026 | msn.comTarsus Pharmaceuticals (NASDAQ:TARS) Earns Buy Rating from HC WainwrightMay 4, 2026 | marketbeat.comPictet Asset Management Holding SA Sells 36,069 Shares of Tarsus Pharmaceuticals, Inc. $TARSMay 4, 2026 | marketbeat.comD.A. Davidson & CO. Takes $1.49 Million Position in Tarsus Pharmaceuticals, Inc. $TARSMay 3, 2026 | marketbeat.comJennison Associates LLC Sells 374,511 Shares of Tarsus Pharmaceuticals, Inc. $TARSApril 30, 2026 | marketbeat.comTarsus Pharmaceuticals (TARS) Expected to Announce Earnings on ThursdayApril 30, 2026 | marketbeat.comTarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026April 29, 2026 | globenewswire.comUniversal Beteiligungs und Servicegesellschaft mbH Increases Holdings in Tarsus Pharmaceuticals, Inc. $TARSApril 27, 2026 | marketbeat.comCalamos Advisors LLC Makes New $2.82 Million Investment in Tarsus Pharmaceuticals, Inc. $TARSApril 27, 2026 | marketbeat.comTarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline ProgressesApril 14, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Alterity Therapeutics (OtherPRNAF), Tarsus Pharmaceuticals (TARS) and enGene Holdings (ENGN)April 4, 2026 | theglobeandmail.comAssessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing LossesApril 3, 2026 | finance.yahoo.comHow TP-05’s Phase 2 Lyme Prophylaxis Trial Progress Could Impact Tarsus Pharmaceuticals (TARS) InvestorsApril 3, 2026 | finance.yahoo.comTarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme DiseaseMarch 31, 2026 | globenewswire.comStocks to watch: Tarsus Pharmaceuticals sees relative strength rating rise to 82March 26, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Climb Bio (CLYM) and Boston Scientific (BSX)March 26, 2026 | theglobeandmail.comTarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked TradeMarch 24, 2026 | fool.comTarsus Pharmaceuticals shares rise on China drug approval milestoneMarch 23, 2026 | za.investing.comTarsus to receive $15M milestone after China approves TP-03 eye therapyMarch 23, 2026 | msn.comTarsus Pharmaceuticals Achieves $15 Million Milestone Payment Following Regulatory Approval of TP-03 in ChinaMarch 23, 2026 | quiverquant.comQ Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TARS Media Mentions By Week TARS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TARS News Sentiment▼0.700.47▲Average Medical News Sentiment TARS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TARS Articles This Week▼54▲TARS Articles Average Week Get the Latest News and Ratings for TARS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Tarsus Pharmaceuticals and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Arrowhead Pharmaceuticals News Elanco Animal Health News Cytokinetics News Abivax News Praxis Precision Medicines News Krystal Biotech News Nuvalent News ImmunityBio News Qiagen News Vaxcyte News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TARS) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
